CY1108396T1 - Μη νουκλεοζιτικοι αναστολεις της αναστροφης μεταγραφασης ως ανταγωνιστες του κυτταρικου πολλαπλασιασμου και επαγωγεις της διαφοροποιησεως των κυτταρων - Google Patents

Μη νουκλεοζιτικοι αναστολεις της αναστροφης μεταγραφασης ως ανταγωνιστες του κυτταρικου πολλαπλασιασμου και επαγωγεις της διαφοροποιησεως των κυτταρων

Info

Publication number
CY1108396T1
CY1108396T1 CY20081101102T CY081101102T CY1108396T1 CY 1108396 T1 CY1108396 T1 CY 1108396T1 CY 20081101102 T CY20081101102 T CY 20081101102T CY 081101102 T CY081101102 T CY 081101102T CY 1108396 T1 CY1108396 T1 CY 1108396T1
Authority
CY
Cyprus
Prior art keywords
transferration
nucleozitic
reversal
influences
components
Prior art date
Application number
CY20081101102T
Other languages
English (en)
Inventor
Corrado Spadafora
Patrizia Lavia
Elisabetta Mattei
Guglielmo Palombini
Rodolfo Nello Lorenzini
Clara Nervi
Original Assignee
Istituto Superiore Di Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITRM20010767 external-priority patent/ITRM20010767A1/it
Priority claimed from ITMI20021833 external-priority patent/ITMI20021833A1/it
Application filed by Istituto Superiore Di Sanita filed Critical Istituto Superiore Di Sanita
Publication of CY1108396T1 publication Critical patent/CY1108396T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αναφέρεται στη χρήση ενώσεων αναστολής της ανάστροφης μεταγραφάσης (RT) για την παρασκευή φαρμακευτικών συνθέσεων για την αντιστάθμιση της απώλειας κυτταρικής διαφοροποιήσεως σε καρκινικές και μη καρκινικές παθήσεις, η οποία ένωση είναι ικανή να συνδέεται με τον υδρόφοβο θύλακα της υπομονάδας p66 της RT. Ιδιαίτερα προτιμώνται γι' αυτές τις χρήσεις οι ακόλουθες ενώσεις: νεβιραπίνη, εφαβιρένζη, δελαβιρδίνη, αντίστοιχα άλατα και/ή φαρμακευτικά αποδεκτά παράγωγα τους.
CY20081101102T 2001-12-24 2008-10-06 Μη νουκλεοζιτικοι αναστολεις της αναστροφης μεταγραφασης ως ανταγωνιστες του κυτταρικου πολλαπλασιασμου και επαγωγεις της διαφοροποιησεως των κυτταρων CY1108396T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM20010767 ITRM20010767A1 (it) 2001-12-24 2001-12-24 Uso di 5.11-diidro-6h-dipirido1/4 3,2-b:2',3'-e|1/4 1.4|diazepine per la preparazione di composizioni farmaceutiche antitumorali.
ITMI20021833 ITMI20021833A1 (it) 2002-08-19 2002-08-19 Inibitori non nucleosidici della trascrittasi inversa come induttori del differenziamento cellulare.
EP02793112A EP1469858B1 (en) 2001-12-24 2002-12-23 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation

Publications (1)

Publication Number Publication Date
CY1108396T1 true CY1108396T1 (el) 2014-02-12

Family

ID=26332794

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101102T CY1108396T1 (el) 2001-12-24 2008-10-06 Μη νουκλεοζιτικοι αναστολεις της αναστροφης μεταγραφασης ως ανταγωνιστες του κυτταρικου πολλαπλασιασμου και επαγωγεις της διαφοροποιησεως των κυτταρων

Country Status (23)

Country Link
US (1) US10507207B2 (el)
EP (1) EP1469858B1 (el)
JP (1) JP4336584B2 (el)
CN (1) CN100450487C (el)
AP (1) AP1958A (el)
AT (1) ATE400276T1 (el)
AU (1) AU2002358793B2 (el)
CA (1) CA2471543C (el)
CY (1) CY1108396T1 (el)
DE (1) DE60227563D1 (el)
DK (1) DK1469858T3 (el)
EA (1) EA007004B1 (el)
ES (1) ES2309222T3 (el)
HK (1) HK1074998A1 (el)
HU (1) HU229522B1 (el)
IL (2) IL162680A0 (el)
MX (1) MXPA04006205A (el)
NZ (1) NZ534257A (el)
OA (1) OA13140A (el)
PL (1) PL211565B1 (el)
PT (1) PT1469858E (el)
SI (1) SI1469858T1 (el)
WO (1) WO2003055493A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081823A1 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as otoprotective agent
CA2796620A1 (en) * 2010-06-04 2011-12-08 North-West University Injectable formulation
US9468646B2 (en) * 2013-01-23 2016-10-18 Alienor Farma Increased dosage of efavirenz for the treatment of cancer
EP3277309A1 (en) 2015-04-03 2018-02-07 Alienor Farma Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
CN113384585A (zh) * 2021-04-16 2021-09-14 蓝龙药业(北京)有限公司 依法韦仑在制备治疗小细胞肺癌的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258839B1 (en) * 1997-12-24 2001-07-10 Peter Mashava Isolation of naturally occuring isoflavanone and some clinical uses thereof

Also Published As

Publication number Publication date
IL162680A (en) 2010-11-30
CA2471543A1 (en) 2003-07-10
US20060166970A1 (en) 2006-07-27
ES2309222T3 (es) 2008-12-16
JP2005513147A (ja) 2005-05-12
HUP0600841A3 (en) 2012-09-28
OA13140A (en) 2006-12-13
SI1469858T1 (sl) 2008-10-31
NZ534257A (en) 2008-03-28
DK1469858T3 (da) 2008-09-29
HK1074998A1 (en) 2005-12-02
HU229522B1 (en) 2014-01-28
CN1607953A (zh) 2005-04-20
PT1469858E (pt) 2008-10-01
AU2002358793B2 (en) 2008-04-24
WO2003055493A1 (en) 2003-07-10
ATE400276T1 (de) 2008-07-15
PL374038A1 (en) 2005-09-19
PL211565B1 (pl) 2012-05-31
US10507207B2 (en) 2019-12-17
EA007004B1 (ru) 2006-06-30
IL162680A0 (en) 2005-11-20
CN100450487C (zh) 2009-01-14
MXPA04006205A (es) 2005-07-25
JP4336584B2 (ja) 2009-09-30
AP2004003088A0 (en) 2004-09-30
EA200400861A1 (ru) 2004-12-30
HUP0600841A2 (en) 2007-05-02
EP1469858A1 (en) 2004-10-27
DE60227563D1 (de) 2008-08-21
EP1469858B1 (en) 2008-07-09
AU2002358793A1 (en) 2003-07-15
AP1958A (en) 2009-02-20
CA2471543C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
NL300877I2 (nl) obeticholzuur
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
EA200200770A1 (ru) Производные пурина
EA200101203A1 (ru) Производные пурина
EA200201291A1 (ru) Производные пурина
TR200101744T2 (tr) Fenilglisin türevleri.
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
CY1108396T1 (el) Μη νουκλεοζιτικοι αναστολεις της αναστροφης μεταγραφασης ως ανταγωνιστες του κυτταρικου πολλαπλασιασμου και επαγωγεις της διαφοροποιησεως των κυτταρων
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
PL374019A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
ATE345349T1 (de) Purinderivate
PT1222159E (pt) Intermediarios de fabricacao de um derivado de tipo benzofurano ou benzotiofeno nitrado em posicao 5 e as suas utilizacoes
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
MXPA05009282A (es) Derivados de anilina sustituidos.
SE9904128D0 (sv) Novel compounds
BR0012329A (pt) Derivados de benzofurano
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas
EA200300238A1 (ru) Триазольные производные и фармацевтические композиции, содержащие их
TR200100954T2 (tr) Alfa-2-antagonistler olarak benzotiyeno[3.2-c]-piridinler
DE69837349D1 (de) Monomer- und dimer-arylisochinolinalkaloide und derivate
EA200601458A1 (ru) Трициклические имидазопиридины и интермедиаты для их синтеза
ECSP993230A (es) Antagonistas iii del receptor ccr-3
CY1114161T1 (el) Ενωσεις ενζυμικης αναστολης
DK1105388T3 (da) N-substituerede azabicycloheptan-derivater, fremstilling og anvendelse heraf